NBIXNeurocrine Biosciences Inc
+0.6% today · −1.0% over a year
9/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 90% of the instruments we score
Quality, Stability: among the best of its peers; priced lower than most peers. No dividend.
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 212)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Gross profit growth / assets (5 y)supports the score · better than 94% of peers
- Gross profit / assetssupports the score · better than 90% of peers
- Volatility (1 y)supports the score · better than 78% of peers
Red flags and notes
No red flagsNone of our published warning rules is triggered right now.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/E
- 19.6
- P/B
- 3.7
- P/S
- 4.1
- EV/EBIT
- 16.9
- Market cap (EUR)
- €123.3億
Profitability and debt
- Return on equity
- 22.1%
- Return on invested capital
- 20.6%
- Gross margin
- 98.0%
- Net debt / EBITDA
- −0.46
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- +0.6%
- 1 month
- −13.6%
- 1 year
- −1.0%
- Volatility, 1 yr
- 33.8%
- Max drawdown, 1 yr
- −27.2%
- Beta
- 0.77
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
News and filings
- NEUROCRINE BIOSCIENCES INC: 8-K — Director or officer change
FactSEC EDGAR · Filing · 29 9月 2026
- NEUROCRINE BIOSCIENCES INC: 8-K/A (amendment) — Financial statements and exhibits
FactSEC EDGAR · Filing · 1 8月 2026
- NEUROCRINE BIOSCIENCES INC: 10-Q — Quarterly report for the period ending 2026-06-30
FactSEC EDGAR · Filing · 31 7月 2026
- NEUROCRINE BIOSCIENCES INC: 8-K — Results of operations
FactSEC EDGAR · Filing · 31 7月 2026
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | 9/10 | 9 · — | — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
ここで契約を解約する · EU消費者向け：購入から14日以内の返品が可能。